Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis
Ning Zhang,1 Changqing Zhang,2 Zhihong Zeng,1 Jiyong Zhang,1 Shengnan Du,1 Chunde Bao,3 Zhe Wang1 1Longwood Biopharmaceuticals, Shanghai, People’s Republic of China; 2Department of Orthopaedics, Shanghai Sixth People’s Hospital, Shanghai, People’s Republic of China; 3De...
Saved in:
Main Authors: | Zhang N (Author), Zhang C (Author), Zeng Z (Author), Zhang J (Author), Du S (Author), Bao C (Author), Wang Z (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022) -
JAK inhibitors: a promising direction for treating Rheumatoid Arthritis
by: Pelechas Eleftherios
Published: (2017) -
Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
by: Cutolo M, et al.
Published: (2013) -
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
by: Harrington R, et al.
Published: (2020) -
Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
by: Martina Biggioggero, et al.
Published: (2019)